Skip to main content
SpringerLink
Log in

Neue ESC-Leitlinien 2021 zur Prävention von kardiovaskulären Erkrankungen

Aufruf zur Prävention

The new ESC guidelines 2021 on prevention of cardiovascular diseases

Appeal for prevention

  • Schwerpunkt
  • Published:
Herz Aims and scope Submit manuscript

Zusammenfassung

Dieser Artikel fasst die Neuerungen und wichtigsten Punkte der kürzlich veröffentlichten und aktualisierten ESC-Leitlinie 2021 zur Prävention von kardiovaskulären Erkrankungen zusammen. Entwicklungen in der Risikostratifizierung sowie Weiterentwicklungen bezüglich Zielen und Optionen der Behandlung von Risikofaktoren bedurften einer Aktualisierung der Leitlinien von 2016. Die Neuerungen beinhalten einen stufenweisen und individualisierten Ansatz der Präventionsziele, eine Implementierung des SCORE2(Systematic Coronary Risk Evaluation [Update])- und SCORE2-OP(Older Persons)-Systems zur Risikostratifizierung inklusive altersabhängiger Abschätzungen für junge (< 50 Jahre) und ältere Menschen (≥ 70 Jahre) sowie bei Patienten mit Diabetes mellitus und atherosklerotischer kardiovaskulärer Erkrankung. Des Weiteren werden spezifische Empfehlungen für koronare Herzkrankheit, Herzinsuffizienz und chronische Niereninsuffizienz gegeben. Neben Empfehlungen zur individuellen Behandlung wird auch die Relevanz der kardiovaskulären Prävention auf Bevölkerungsebene inklusive Umweltschutz unterstrichen.

Abstract

This article summarizes the innovations and most important points of the recently published and updated ESC guidelines 2021 on the prevention of cardiovascular diseases. Developments in risk stratification and further developments with respect to targets and options for the treatment of risk factors necessitated an update of the guidelines from 2016. The innovations incorporate a staged and individualized approach to the prevention targets, an implementation of the systematic coronary risk evaluation 2 (SCORE 2 update) and the SCORE 2‑older persons (OP) systems on risk stratification, including age-dependent estimations for young (<50 years old) and older people (≥70 years old) as well as for patients with diabetes mellitus and atherosclerotic cardiovascular diseases. Furthermore, specific recommendations are given for coronary heart disease, heart failure and chronic kidney insufficiency. In addition to recommendations on individualized treatment, the relevance of cardiovascular prevention at the population level, including environmental protection is underlined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Visseren FLJ, Mach F, Smulders YM et al (2021) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42(34):3227

    Article  Google Scholar 

  2. Kivimaki M, Steptoe A (2018) Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol 15(4):215–229

    Article  CAS  Google Scholar 

  3. De Hert M, Detraux J, Vancampfort D (2018) The intriguing relationship between coronary heart disease and mental disorders. Dialogues Clin Neurosci 20(1):31–40

    Article  Google Scholar 

  4. Pandey A, Kitzman D, Reeves G (2019) Frailty is intertwined with heart failure: mechanisms, prevalence, prognosis, assessment, and management. JACC Heart Fail 7(12):1001–1011

    Article  Google Scholar 

  5. Forman DE, Maurer MS, Boyd C et al (2018) Multimorbidity in older adults with cardiovascular disease. J Am Coll Cardiol 71(19):2149–2161

    Article  Google Scholar 

  6. Stein JH, Korcarz CE, Hurst RT et al (2008) Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American society of echocardiography carotid Intima-media thickness task force. Endorsed by the society for vascular medicine. J Am Soc Echocardiogr 21(2):93–111 (quiz 89–90)

    Article  Google Scholar 

  7. Chen Z, Schunkert H (2021) Genetics of coronary artery disease in the post-GWAS era. J Intern Med 290(5):980–992

    Article  Google Scholar 

  8. Lelieveld J, Pozzer A, Poschl U et al (2020) Loss of life expectancy from air pollution compared to other risk factors: a worldwide perspective. Cardiovasc Res 116(11):1910–1917

    Article  CAS  Google Scholar 

  9. Hahad O, Kröller-Schön S, Daiber A, Münzel T (2019) The cardiovascular effects of noise. Dtsch Arztebl Int 116(14):245–250

    PubMed  PubMed Central  Google Scholar 

  10. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382(9889):339–352

    Article  Google Scholar 

  11. Hindricks G, Potpara T, Dagres N et al (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association of cardio-thoracic surgery (EACTS). Eur Heart J 42(5):373–498

    Article  Google Scholar 

  12. Chung MK, Eckhardt LL, Chen LY et al (2020) Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American heart association. Circulation 141(16):e750–e72

    Article  Google Scholar 

  13. Seferovic PM, Ponikowski P, Anker SD et al (2019) Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the heart failure association of the European society of cardiology. Eur J Heart Fail 21(10):1169–1186

    Article  Google Scholar 

  14. Zamorano JL, Lancellotti P, Rodriguez Munoz D et al (2017) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur J Heart Fail 19(1):9–42

    Article  Google Scholar 

  15. Halle M, Haykowsky M (2018) Atrial fibrillation: a preventable lifestyle disease! Eur J Prev Cardiol 25(15):1642–1645

    Article  Google Scholar 

  16. Piepoli MF, Hoes AW, Agewall S et al (2016) 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J 37(29):2315–2381

    Article  Google Scholar 

  17. Trinder M, Li X, DeCastro ML et al (2019) Risk of premature atherosclerotic disease in patients with monogenic versus polygenic familial hypercholesterolemia. J Am Coll Cardiol 74(4):512–522

    Article  Google Scholar 

  18. Williams B, Mancia G, Spiering W et al (2018) 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of cardiology (ESC) and the European society of hypertension (ESH). Eur Heart J 39(33):3021–3104

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lehrstuhl für Präventive und Rehabilitative Sportmedizin, Klinikum rechts der Isar, Technische Universität München, Georg-Brauchle-Ring 56, 80992, München, Deutschland

    Isabel Fegers-Wustrow, Fritz Wimbauer &  Martin Halle

  2. DZHK Partner Site, Munich Heart Alliance, München, Deutschland

    Isabel Fegers-Wustrow &  Martin Halle

Authors
  1. Isabel Fegers-Wustrow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fritz Wimbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Halle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Halle.

Ethics declarations

Interessenkonflikt

I. Fegers-Wustrow, F. Wimbauer und M. Halle geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fegers-Wustrow, I., Wimbauer, F. & Halle, M. Neue ESC-Leitlinien 2021 zur Prävention von kardiovaskulären Erkrankungen. Herz 47, 55–62 (2022). https://doi.org/10.1007/s00059-021-05094-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00059-021-05094-3

Schlüsselwörter

Keywords

Search

Navigation